New AI model can evaluate invasive breast cancer outcomes
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
List view / Grid view
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
Eliminating AT1-like cells in experimental models has shown potential to improve KRAS inhibitor treatment for lung adenocarcinoma.
New imaging technology called fluorescence lifetime (FLT) imaging improves the accuracy of cancer surgery for multiple tumour types.
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
Findings from using a 3D hydrogel to study how cancer cells physically tear the basement membrane offers promise for targeted treatment.
Researchers find that polymerase epsilon exonuclease is an essential target for cancer diagnosis and treatments that rely on DNA damage.
New understanding of how lung cancer cells become more aggressive when nutrient deprived could lead to novel combination treatments.
Percent necrosis calculated with machine learning model for patients with osteosarcoma provides an accurate prognosis for survival.
Mammary organoid cultures show the effects of BRCA2 mutations on breast tissue cells, increasing the likelihood of early, targeted treatment.
Excessive insulin levels in people with obesity and type 2 diabetes overstimulates pancreatic cells, initiating disease.
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.
Researchers have developed a new bioreactor that can manufacture T cells faster than other technologies, which may advance immunotherapy.